Navigation Links
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN

Interim analysis of Phase 2 comparative study showed significant results in favor of alemtuzumab versus Rebif

CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007 /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCare Pharmaceutical today announced detailed interim results from the CAMMS223 Phase 2 study. This interim analysis of all patient data through at least twenty-four months from the start of the study for all patients showed that a once-yearly cycle of alemtuzumab treatment had a statistically significant impact on reducing the frequency of relapses and the sustained accumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Rebif(R) (interferon beta-1a).

The data were presented yesterday at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston by Dr. Alasdair J. Coles, Ph.D., MRCP, Addenbrooke's Hospital, University of Cambridge, United Kingdom. This is the first time that an analysis of the primary and secondary endpoints has been presented in full.

Dr. Coles' presentation showed patients taking alemtuzumab at the high dose experienced an 87 percent reduction in the risk for relapse (p<0.0001) and a 66 percent reduction in the risk for progression of clinically significant disability (p<0.0098) when compared to patients treated with Rebif. At the low dose, patients taking alemtuzumab experienced similar results, with a 72 percent reduction in the risk for relapse (p<0.0001) and an 88 percent reduction in the risk for progression of clinically significant disability (p<0.0008) compared with patients treated with Rebif. Patients in both alemtuzumab arms also achieved a statistically significant reduction in disability compared with their pre-treatment baseline, as measured by their Extended Disability Status Scale (EDSS) scores.

"Although several therapies are already available to treat MS, patients stil
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... MURRAY HILL and NEW PROVIDENCE, ... management and engineering professionals are invited to meet with ... Conference and Technical Exhibition to be held at McCormick ... August 3-6. "Hospitals demand nothing less ... said Mark Sanda , Linde,s Healthcare Segment manager. ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... , DENVER , Jan. 28 Global ... Board: GLOB), an international healthcare information technology company, today announced ... management software and Donor Doc® health history questionnaire to Community ... Kansas City, Missouri . Terms of the agreement were ...
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
Cached Medicine Technology:Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 2Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 3Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 4Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 5ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4
(Date:7/28/2014)... A January 2013 study published ... in those who were self-diagnosed gluten-intolerant yielded little verifiable ... for San Diego health and wellness retreat VeraVia ... those who are unclear about the role gluten plays ... a protein, found in wheat, barley, rye, and triticale. ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... just milliseconds to look at someone,s face and judge them ... that certain facial features seem to trigger specific first impressions ... of the mouth, for example, appear directly linked to whether ... The study findings suggest that first impressions are ...
(Date:7/28/2014)... 28, 2014 Shofner Vision Center ... June . Renowned LASIK and Cataract Surgeon, Dr. ... significant funds and public awareness for local not-for-profit ... personnel and their families. “This was our 2nd ... nearly $5,000 to a variety of local not-for-profit ...
(Date:7/28/2014)... 2014 (HealthDay News) --,The more chronic medical conditions people ... may be, a new study claims. Since ... issues, scientists at Johns Hopkins Bloomberg School of Public ... why gains in life expectancy are slowing in the ... as diabetes, kidney disease and heart failure is now ...
(Date:7/28/2014)... SIMpalm helped its client to launch ... on iTunes for download . Experience a new way ... you to listen and cook along with expert real-time audio ... out the ingredients and equipment, press play, and follow the ... ahead of time, just relax and cook along with us. ...
Breaking Medicine News(10 mins):Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4
... Calif., July 9 Exponent, Inc.,(Nasdaq: EXPO ), ... second quarter ended June 27, 2008, immediately following the ... Company will host a,corresponding conference call and live webcast ... Gaulke, Chairman and Chief Executive,Officer, and Richard Schlenker, Chief ...
... That Protect Patient Access To Community,Pharmacies, ... Senate,today voted by unanimous consent in favor ... and Providers Act of 2008 contains three ... Part D claims, delayed cuts to Medicaid ...
... Infection toll at 1,017; health officials add hot peppers ... WEDNESDAY, July 9 (HealthDay News) -- The number of ... surpassed 1,000, and while certain types of tomatoes remain ... hot peppers and cilantro as potential suspects. , ...
... doesn,t improve death rates, study finds , , WEDNESDAY, July ... of patients whose lungs fill with water because of ... a new British study shows. , The study found ... -- continuous positive airway pressure (CPAP) and noninvasive intermittent ...
... CEO of the American,Association for Homecare, ARLINGTON, ... providers are just as appalled as lawmakers and,Medicare ... identification,numbers from deceased doctors to bilk millions of ... and manufacturers represented by,the American Association for Homecare ...
... The #1 Safety Hazard in Most Hospitals, WASHINGTON, July ... at CHRISTUS Spohn Health System (Corpus Christi TX),received overdoses of ... CDT,one of the babies has died; another is in critical ... why computerized systems for,ordering medication in hospitals has been The ...
Cached Medicine News:Health News:Salmonella Illnesses Now Top 1,000 2Health News:Salmonella Illnesses Now Top 1,000 3Health News:Assisted Breathing Eases Lung Symptoms for Heart Patients 2Health News:Home Medical Equipment Providers Are Appalled by 'Dead-Doctor' Scam, Strongly Support Anti-Fraud Efforts to Protect Medicare System 2Health News:Home Medical Equipment Providers Are Appalled by 'Dead-Doctor' Scam, Strongly Support Anti-Fraud Efforts to Protect Medicare System 3Health News:Statement of the Leapfrog Group on Hospital Overdose of Up to 17 Babies at CHRISTUS Spohn 2
PremierEdge Stab Knives - 15....
DCR Set, Straight....
... acknowledged to be the easiest to use, ... benefits are due to the exclusive use ... footprint available coupled with advanced electronics and ... reading. Thus corneal thickness measurements can be ...
... The Leica CM1850 cryostat for ... histopathology laboratory is designed for ... workload. A new insulation technology ... the refrigerating system and maintains ...
Medicine Products: